UA78738C2 - Composition containing cowpox virus and method for its preparation - Google Patents
Composition containing cowpox virus and method for its preparation Download PDFInfo
- Publication number
- UA78738C2 UA78738C2 UA20040705588A UA20040705588A UA78738C2 UA 78738 C2 UA78738 C2 UA 78738C2 UA 20040705588 A UA20040705588 A UA 20040705588A UA 20040705588 A UA20040705588 A UA 20040705588A UA 78738 C2 UA78738 C2 UA 78738C2
- Authority
- UA
- Ukraine
- Prior art keywords
- composition
- temperature
- product
- composition according
- buffer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 182
- 238000000034 method Methods 0.000 title claims abstract description 48
- 241000700626 Cowpox virus Species 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000872 buffer Substances 0.000 claims abstract description 39
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 27
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims description 31
- 229960005486 vaccine Drugs 0.000 claims description 30
- 238000004108 freeze drying Methods 0.000 claims description 29
- 241000700618 Vaccinia virus Species 0.000 claims description 22
- 229930006000 Sucrose Natural products 0.000 claims description 21
- 239000005720 sucrose Substances 0.000 claims description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 19
- 229920002307 Dextran Polymers 0.000 claims description 18
- 238000007710 freezing Methods 0.000 claims description 12
- 230000008014 freezing Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 7
- 238000000859 sublimation Methods 0.000 claims description 7
- 230000008022 sublimation Effects 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000000047 product Substances 0.000 description 79
- 241000700605 Viruses Species 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 230000003612 virological effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 241000700647 Variola virus Species 0.000 description 12
- 230000008569 process Effects 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000013024 dilution buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000700663 Avipoxvirus Species 0.000 description 3
- 239000004484 Briquette Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000700629 Orthopoxvirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000005585 Poxviridae Infections Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000005443 coulometric titration Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229940083538 smallpox vaccine Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- FHYAUNJNVMGZQN-NHCUHLMSSA-N (2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(I)C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 FHYAUNJNVMGZQN-NHCUHLMSSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010040864 CERE Proteins 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- -1 glucose Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- OJLGASCOGOIOJR-UHFFFAOYSA-N soyasaponin gammag Natural products CC1=C(O)C(=O)CC(OC2CC(C)(C)CC3C4=CCC5C6(C)CCC(OC7OC(C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(=O)O)C(C)(CO)C6CCC5(C)C4(C)CCC23C)O1 OJLGASCOGOIOJR-UHFFFAOYSA-N 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101831 | 2001-12-10 | ||
| PCT/EP2002/013434 WO2003053463A2 (en) | 2001-12-10 | 2002-11-28 | Poxvirus-containing compositions and process for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA78738C2 true UA78738C2 (en) | 2007-04-25 |
Family
ID=8160885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705588A UA78738C2 (en) | 2001-12-10 | 2002-11-28 | Composition containing cowpox virus and method for its preparation |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7094412B2 (da) |
| EP (1) | EP1418942B1 (da) |
| JP (1) | JP4439263B2 (da) |
| KR (1) | KR20040074067A (da) |
| CN (1) | CN1296096C (da) |
| AT (1) | ATE300954T1 (da) |
| AU (1) | AU2002361962A1 (da) |
| BR (1) | BR0214822A (da) |
| CA (1) | CA2467365C (da) |
| DE (1) | DE60205388T2 (da) |
| DK (1) | DK1418942T3 (da) |
| EA (1) | EA006880B1 (da) |
| ES (1) | ES2247414T3 (da) |
| HK (1) | HK1071295A1 (da) |
| HU (1) | HUP0402179A3 (da) |
| IL (2) | IL161590A0 (da) |
| MX (1) | MXPA04005577A (da) |
| NO (1) | NO20042958L (da) |
| NZ (1) | NZ533302A (da) |
| PL (1) | PL213326B1 (da) |
| UA (1) | UA78738C2 (da) |
| WO (1) | WO2003053463A2 (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| PT1434858E (pt) | 2002-09-05 | 2008-07-28 | Bavarian Nordic As | Método de amplificação de um poxvírus em condições sem soro |
| CN1207005C (zh) * | 2002-10-31 | 2005-06-22 | 威世药业（如皋）有限公司 | 含生物活性物质的兔皮和其用途 |
| WO2006029467A1 (en) * | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
| CN101360821A (zh) * | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| AU2008250596C1 (en) | 2007-05-14 | 2010-11-25 | Bavarian Nordic A/S | Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines |
| BRPI0811161A2 (pt) * | 2007-05-18 | 2014-10-07 | Medimmune Llc | Conservação de materiais bioativos por espuma liofilizada. |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| KR20120093941A (ko) | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성 |
| KR20130008645A (ko) | 2010-05-21 | 2013-01-22 | 에이에이치 유에스에이 42 엘엘씨 | 광견병 바이러스 항원을 함유하는 파라폭스바이러스 벡터 |
| JP2013537409A (ja) | 2010-07-20 | 2013-10-03 | ゾエティス・エルエルシー | パラポックスウイルスベクター |
| CA2802430C (en) | 2010-07-20 | 2021-07-20 | Bavarian Nordic A/S | Method for harvesting poxvirus |
| EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| BR112015000530A2 (pt) | 2012-07-10 | 2018-08-28 | Transgene Sa | vacina de antígeno micobacteriano. |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2015104380A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| EP3116541B1 (en) | 2014-03-12 | 2019-11-27 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| DK3226894T3 (da) | 2014-12-01 | 2019-10-21 | Transgene Sa | Stabile flydende vacciniavirus-formuleringer |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
| CN110603058A (zh) | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| KR102658198B1 (ko) * | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法 |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| BR112020018117A2 (pt) | 2018-03-07 | 2020-12-22 | Transgene | Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| US20210386807A1 (en) | 2018-10-30 | 2021-12-16 | The University Of Tokyo | Oncolytic virus for cancer therapy |
| CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| CN115243717A (zh) | 2020-03-12 | 2022-10-25 | 巴法里安诺迪克有限公司 | 改善痘病毒稳定性的组合物 |
| US12029787B2 (en) | 2020-07-01 | 2024-07-09 | University Of Connecticut | Method for generating recombinant poxviruses |
| CA3189238A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2024003238A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | Epstein-barr-virus vaccine |
| WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
| WO2024149832A1 (en) | 2023-01-12 | 2024-07-18 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| WO2024188801A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
| WO2024188803A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Production of poxviruses from quail cell cultures |
| WO2024188802A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE299213C (da) | ||||
| US4380582A (en) * | 1965-07-09 | 1983-04-19 | The United States Of America As Represented By The Secretary Of The Army | Preparation of dry variola virus |
| FR7773M (da) * | 1968-06-14 | 1970-03-23 | ||
| US3577526A (en) * | 1969-06-13 | 1971-05-04 | Merieux Inst | Stabilized smallpox vaccine |
| US3915794A (en) | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
| CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| MY150893A (en) * | 1996-09-24 | 2014-03-14 | Bavarian Nordic As | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
-
2002
- 2002-11-28 US US10/496,858 patent/US7094412B2/en not_active Expired - Lifetime
- 2002-11-28 NZ NZ533302A patent/NZ533302A/en not_active IP Right Cessation
- 2002-11-28 KR KR10-2004-7008900A patent/KR20040074067A/ko active Search and Examination
- 2002-11-28 EP EP02796552A patent/EP1418942B1/en not_active Revoked
- 2002-11-28 BR BR0214822-6A patent/BR0214822A/pt active Search and Examination
- 2002-11-28 IL IL16159002A patent/IL161590A0/xx unknown
- 2002-11-28 HU HU0402179A patent/HUP0402179A3/hu unknown
- 2002-11-28 EA EA200400796A patent/EA006880B1/ru not_active IP Right Cessation
- 2002-11-28 ES ES02796552T patent/ES2247414T3/es not_active Expired - Lifetime
- 2002-11-28 DK DK02796552T patent/DK1418942T3/da active
- 2002-11-28 CA CA2467365A patent/CA2467365C/en not_active Expired - Fee Related
- 2002-11-28 MX MXPA04005577A patent/MXPA04005577A/es active IP Right Grant
- 2002-11-28 DE DE60205388T patent/DE60205388T2/de not_active Expired - Lifetime
- 2002-11-28 AT AT02796552T patent/ATE300954T1/de active
- 2002-11-28 PL PL369954A patent/PL213326B1/pl unknown
- 2002-11-28 WO PCT/EP2002/013434 patent/WO2003053463A2/en active IP Right Grant
- 2002-11-28 CN CNB028246780A patent/CN1296096C/zh not_active Expired - Fee Related
- 2002-11-28 JP JP2003554220A patent/JP4439263B2/ja not_active Expired - Fee Related
- 2002-11-28 UA UA20040705588A patent/UA78738C2/uk unknown
- 2002-11-28 AU AU2002361962A patent/AU2002361962A1/en not_active Abandoned
-
2004
- 2004-04-22 IL IL161590A patent/IL161590A/en not_active IP Right Cessation
- 2004-07-09 NO NO20042958A patent/NO20042958L/no not_active Application Discontinuation
-
2005
- 2005-05-13 HK HK05104050A patent/HK1071295A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60205388T2 (de) | 2006-03-30 |
| KR20040074067A (ko) | 2004-08-21 |
| AU2002361962A1 (en) | 2003-07-09 |
| WO2003053463A2 (en) | 2003-07-03 |
| US7094412B2 (en) | 2006-08-22 |
| BR0214822A (pt) | 2004-12-14 |
| HK1071295A1 (en) | 2005-07-15 |
| EA006880B1 (ru) | 2006-04-28 |
| WO2003053463A3 (en) | 2004-03-04 |
| CN1602205A (zh) | 2005-03-30 |
| CN1296096C (zh) | 2007-01-24 |
| EA200400796A1 (ru) | 2004-12-30 |
| EP1418942A2 (en) | 2004-05-19 |
| IL161590A0 (en) | 2004-09-27 |
| ES2247414T3 (es) | 2006-03-01 |
| CA2467365A1 (en) | 2003-07-03 |
| JP4439263B2 (ja) | 2010-03-24 |
| DK1418942T3 (da) | 2005-11-28 |
| CA2467365C (en) | 2012-11-20 |
| JP2005513109A (ja) | 2005-05-12 |
| HUP0402179A3 (en) | 2012-09-28 |
| IL161590A (en) | 2009-06-15 |
| NO20042958L (no) | 2004-07-09 |
| MXPA04005577A (es) | 2005-04-19 |
| PL369954A1 (en) | 2005-05-02 |
| PL213326B1 (pl) | 2013-02-28 |
| US20050019349A1 (en) | 2005-01-27 |
| DE60205388D1 (de) | 2005-09-08 |
| NZ533302A (en) | 2005-11-25 |
| EP1418942B1 (en) | 2005-08-03 |
| HUP0402179A2 (hu) | 2005-01-28 |
| ATE300954T1 (de) | 2005-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA78738C2 (en) | Composition containing cowpox virus and method for its preparation | |
| JP2005513109A6 (ja) | ポックスウイルス含有調合物およびその調製方法 | |
| US8313897B2 (en) | Method for preserving viral particles | |
| ES2373238T3 (es) | Estabilizadores para vacunas liofilizadas. | |
| CN110478479B (zh) | 用于活的减毒病毒的方法和组合物 | |
| US9187729B2 (en) | Alphavirus and alphavirus replicon particle formulations and methods | |
| US10201600B2 (en) | Process for preparing an attenuated tetravalent dengue vaccine | |
| EA006485B1 (ru) | Способ выделения и очистки поксвирусов из инфицированных клеток | |
| CN105377293B (zh) | 减毒活甲病毒制剂的组合物和方法 | |
| KR102544928B1 (ko) | 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도 | |
| NZ525117A (en) | Vaccine composition stabilised by addition of high-molecular-weight polyvinylpyrrolidone, in particular PVF360 whose molecular weight is 360 000 daltons | |
| RU2657801C1 (ru) | Комбинированная вакцина для иммунопрофилактики кори, эпидемического паротита и краснухи | |
| AU2008201215B2 (en) | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |